PCRX — Pacira BioSciences, Inc. stock price, charts and financials

NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·USA

Latest market price

27.62

+0.70+2.60%

Overview Short InterestFilings

PCRXQT53Pacira BioSciences, Inc.·NASDAQ

Overview Short InterestFilings

27.62+2.60%

Filing

Up 2.6% — Filed an 8-K material-event report (2026-08-04) — details in the filing.

Medium confidence

Loading chart...

Signal & projected range

QT Score downgradeHistorical pattern — not a prediction

Range still being built for this setupWe don’t yet have a frozen historical track record for qt score downgrade to describe a reliable spread of outcomes. The projected range appears once its backtest is established.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

CRON-0.71%$2.81 COLL+0.42%$35.73 ETON+1.53%$45.83 ALVO+1.32%$3.84 AMPH-1.58%$19.90 PAHC-1.51%$36.59 HROW+1.89%$39.83 PRGO+0.94%$10.78

Snapshot

Index	-	P/E	-	EPS (ttm)	0.12	Insider Own	6.97%	Shs Outstand	39.34M	Perf Week	3.02%

Market Cap	1.09B	Forward P/E	7.64	EPS next Y	3.61	Insider Trans	-1.54%	Shs Float	37.68M	Perf Month	7.93%

Enterprise Value	1.30B	PEG	14.19	EPS next Q	-	Inst Own	-	Short Float	18.48%	Perf Quarter	11.87%

Income	5.00M	P/S	1.48	EPS this Y	2297.85%	Inst Trans	-	Short Ratio	13.32	Perf Half Y	30.16%

Sales	735.00M	P/B	1.66	EPS next Y	25.63%	ROA	0.43%	Short Interest	6.96M	Perf YTD	6.72%

Book/sh	16.63	P/C	5.38	EPS next 5Y	16.22%	ROE	0.73%	52W High	27.66 -0.14%	Perf Year	25.15%

Cash/sh	5.14	P/FCF	7.83	EPS past 3/5Y	-22.22% -45.51%	ROIC	0.80%	52W Low	18.80 46.91%	Perf 3Y	-22.81%

Dividend Est.	-	EV/EBITDA	10.99	Sales past 3/5Y	2.87% 11.04%	Gross Margin	79.34%	Volatility	4.07% 3.44%	Perf 5Y	-53.42%

Dividend TTM	-	EV/Sales	1.76	EPS Y/Y TTM	105.58%	Oper. Margin	3.09%	ATR (14)	0.94	Perf 10Y	-26.66%

Dividend Ex-Date	-	Quick Ratio	3.35	Sales Y/Y TTM	4.85%	Profit Margin	0.70%	RSI (14)	69.04	Recom	2.69

Dividend Gr. 3/5Y	-	Current Ratio	4.73	EPS Q/Q	-3.23%	SMA20	6.29%	Beta	0.26	Target Price	32.00

Payout	0.00%	Debt/Eq	0.66	Sales Q/Q	4.73%	SMA50	12.30%	Rel Volume	2.17	Prev Close	26.92

Employees	825	LT Debt/Eq	0.64	Earnings	Nov 05	SMA200	17.40%	Avg Volume	520.26K	Price	27.62

IPO Date	Feb 03, 2011	Option/Short	Yes / Yes	EPS/Sales Surpr.	9.57% 3.25%	Net Debt/EBITDA	2.25	Volume	1,130,088	Change	2.60%

Analyst Ratings

Date	Action	Analyst	Rating	Target
May-01-26	Reiterated	Needham	Buy	$63 → $32
Dec-08-25	Initiated	Barclays	Equal Weight	$24 → $27
Feb-28-25	Reiterated	HC Wainwright & Co.	Buy	$57 → $48
Feb-28-25	Reiterated	Barclays	Overweight	$24
Jan-30-25	Upgrade	Truist Securities	Sell → Hold	$8.00 → $25
Nov-07-24	Reiterated	Piper Sandler	Overweight	$42 → $12
Sep-24-24	Reiterated	Jefferies	Buy	$36 → $18
Aug-13-24	Downgrade	Truist Securities	Buy → Sell	$8.00
Aug-12-24	Downgrade	JP Morgan	Overweight → Underweight
Aug-12-24	Downgrade	RBC Capital	Outperform → Sector Perform

Latest News

Aug-04-26

Aug-04-2606:41PM

Pacira (PCRX) Tops Q2 Earnings and Revenue Estimateszacks.com

04:01PM

Pacira BioSciences Reports Second Quarter 2026 Financial Resultsglobenewswire.com

Aug-03-26

Aug-03-2605:18AM

First Trust Advisors LP Grows Position in Pacira BioSciences, Inc. $PCRXdefenseworld.net

Jul-27-26

Jul-27-2608:03AM

Pacira BioSciences Successfully Transitions PCRX-201 To A Scalable Commercial Manufacturing Process In The U.S.; Topline Data From Part A Of Phase 2 ASCEND Study Remains On Track For End Of 2026Benzinga

08:00AM

Pacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Processglobenewswire.com

Jul-26-26

Jul-26-2601:59AM

Brokerages Set Pacira BioSciences, Inc. (NASDAQ:PCRX) Price Target at $29.40defenseworld.net

Jul-22-26

Jul-22-2608:00AM

Pacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026globenewswire.com

Jul-08-26

Jul-08-2608:00AM

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com

Jul-01-26

Jul-01-2610:30AM

Pacira to Divest iovera Business to Zimmer Biomet in Up To $140M Dealzacks.com

08:15AM

HC Wainwright & Co. Reiterates Buy on Pacira BioSciences, Maintains $38 Price TargetBenzinga

08:00AM

Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL®globenewswire.com

Jun-30-26

Jun-30-2607:30AM

Pacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer Biometglobenewswire.com

Company

Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	735	726	701	675	667	542	430	421	337
Cost of Goods Sold Incl. D&A	151	150	170	185	199	140	117	107	87
Gross Profit	583	577	531	490	468	401	312	314	250
Selling, General and Administrative Excl. Other	377	369	294	269	255	199	194	201	177
Research and Development	119	117	82	76	85	56	59	72	56
Other Operating Expense	64	57	228	58	68	56	13	31	0
Operating Income	22	33	-73	88	60	90	46	10	16
Interest Expense	15	15	17	17	36	29	26	24	22
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	6	-2	27	-9	-11	-5	-1	2	6
Net Income Before Taxes	14	17	-63	62	13	56	20	-11	0
Income Taxes	8	10	36	20	-3	14	-125	0	0
Consolidated Net Income	5	7	-100	42	16	42	146	-11	0
Net Income From Continuing Operations	5	7	-100	42	16	42	146	-11	0
Net Income	5	7	-100	42	16	42	146	-11	0
EPS (Recurring)	0.12	0.16	-2.15	0.91	0.35	0.95	3.41	-0.27	-0.01
EPS (Basic, Before Extraordinaries)	0.12	0.16	-2.15	0.91	0.35	0.95	3.41	-0.27	-0.01
EPS (Diluted)	0.12	0.16	-2.15	0.89	0.34	0.92	3.33	-0.27	-0.01
EBITDA	118	123	29	155	140	114	64	31	33
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	230.17	161.75	—	37.91	113.56	65.40	17.97	—	—
Price To Sales Ratio	1.50	1.60	1.24	2.30	2.66	4.88	5.98	4.52	5.23
Gross Margin	79.32	79.48	75.75	72.59	70.16	73.99	72.56	74.58	74.18
Operating Margin	2.99	4.55	-10.41	13.04	9.00	16.61	10.70	2.38	4.75
Net Margin	0.68	0.96	-14.27	6.22	2.40	7.75	33.95	-2.61	0.00
Shares Outstanding	40	45	46	46	46	44	43	42	41
Market Capitalization	1,105	1,165	867	1,552	1,776	2,647	2,573	1,903	1,764
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RIKER LAUREN	Senior Vice President, Finance	Jun 11 '26	Sale	23.50	6,115	143,703	62,284	Jun 12
WILLIAMS KRISTEN	Chief Administrative Officer	Jun 04 '26	Sale	22.27	10,259	228,468	167,062	Jun 05
Cross Shawn	Chief Financial Officer	Apr 23 '26	Option Exercise	16.45	12,941	212,879	118,282	Apr 24
Cross Shawn	Chief Financial Officer	Apr 23 '26	Sale	25.16	12,941	325,596	105,341	Apr 24
Cross Shawn	Chief Financial Officer	Apr 22 '26	Sale	25.01	1,500	37,515	105,341	Apr 22
Cross Shawn	Chief Financial Officer	Apr 22 '26	Option Exercise	16.45	1,500	24,675	106,841	Apr 22
Cross Shawn	Chief Financial Officer	Apr 21 '26	Option Exercise	16.45	2,845	46,800	108,186	Apr 22
Cross Shawn	Chief Financial Officer	Apr 20 '26	Sale	25.14	7,714	193,930	105,341	Apr 22
Cross Shawn	Chief Financial Officer	Apr 20 '26	Option Exercise	16.45	7,714	126,895	113,055	Apr 22
SLONIN JONATHAN	Chief Medical Officer	Mar 17 '26	Sale	22.82	3,261	74,416	223,640	Mar 19
Froimson Mark	Director	Mar 17 '26	Sale	21.81	500	10,905	20,136	Mar 19
RIKER LAUREN	Senior Vice President, Finance	Feb 02 '26	Sale	20.81	4,000	83,240	52,313	Feb 03
WILLIAMS KRISTEN	Chief Administrative Officer	Feb 02 '26	Sale	20.53	13,137	269,703	131,303	Feb 03
RIKER LAUREN	Senior Vice President, Finance	Jan 05 '26	Sale	24.24	1,416	34,324	59,064	Jan 06
Cross Shawn	Chief Financial Officer	Dec 10 '25	Sale	25.14	9,104	228,875	56,250	Dec 11

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.